Full Length ArticleProtective effects of PITUITARY ADENYLATE CYCLASE ACTIVATING (cas 136134-68-4) polypeptide against neurotoxic agents

Add time:09/02/2019    Source:sciencedirect.com

PITUITARY ADENYLATE CYCLASE ACTIVATING (cas 136134-68-4) polypeptide (PACAP) is a neuropeptide highly expressed in the central and peripheral nervous system, where it exerts several neuromodulatory functions and is an important trophic and protective factor. PACAP has been shown to activate several protective pathways, mainly through its specific PAC1 receptor and protein kinase A, C and MAP kinases downstream. It has been shown to have very potent neuroprotective actions against different neurotoxic agents both in vitro and in vivo. The aim of the present review is to provide an overview on the neurotoxic injuries against which PACAP exerts protection, and to give an insight into its protective mechanism. We give a summary of the neuroprotective effects against the most commonly used neurotoxic agents, such as 6-OHDA, MPTP, glutamate and some less well-known neurotoxic compounds. Also endogenous PACAP has neuroprotective effects, known from studies in PACAP knockout mice or from blocking endogenous effects by antagonists. Altogether, the vast amount of data for the neuroprotective effects of PACAP give a firm background for its endogenous role as part of the neuroprotective machinery and its possible future therapeutic use as a neuroprotective factor.

We also recommend Trading Suppliers and Manufacturers of PITUITARY ADENYLATE CYCLASE ACTIVATING (cas 136134-68-4). Pls Click Website Link as below: cas 136134-68-4 suppliers

Prev:Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor
Next:Pituitary adenylate cyclase-activating polypeptide is a potent broad-spectrum antimicrobial peptide: Structure-activity relationships)